February 9, 2016 – 2016 BIO CEO & Investor Conference – OncBioMune Pharmaceuticals CEO Dr. Jonathan Head presented at the 2016 BIO CEO & Investor Conference held at the Waldorf Astoria in New York City. Dr. Head’s presentation provided a corporate overview of OncBioMune and provided details on the company’s promising pipeline of drugs in development, including ProscaVax, OncBioMune’s novel vaccine in clinical trials as a new therapy for early stage prostate cancer patients.  View the Presentation

October 16, 2015 – “A Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in PSA defined biochemical recurrent prostate cancer patients” – presented at CRI-CIMT-EATI-AACR: Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival meeting in New York City.  View the Presentation